Gastrin I (human): Novel Insights into CCK2 Receptor Signaling and Intestinal Organoid Modeling

Introduction

Gastrin I (human), a potent endogenous peptide, has long been recognized as a principal regulator of gastric acid secretion via its interaction with the cholecystokinin-2 (CCK2) receptor. While prior research has elucidated its role as a gastric acid secretion regulator and its capacity to activate proton pumps in parietal cells, recent advances in stem cell-derived intestinal organoid technology have catalyzed a paradigm shift in experimental gastrointestinal physiology. This article bridges the mechanistic understanding of Gastrin I (human) (SKU: B5358) with the forefront of organoid-based research, offering new frameworks for gastrointestinal physiology studies and translational research into gastrointestinal disorders. Unlike prior articles that focus predominantly on proton pump signaling or assay protocol enhancements, our analysis uniquely explores the integration of Gastrin I signaling within human pluripotent stem cell-derived intestinal organoid models, as recently advanced by Saito et al. (2025), thereby illuminating novel pathways for experimental pharmacology and disease modeling.

Gastrin I (human): Structure, Biochemical Properties, and Receptor Interactions

Molecular Features and Preparation

Gastrin I (human) is an endogenous peptide (CAS: 10047-33-3; MW: 2098.22 Da) supplied as a white lyophilized solid. Notably, it is insoluble in water and ethanol but dissolves readily in DMSO at concentrations ≥21 mg/mL, facilitating its use in advanced in vitro systems. Its purity, confirmed to be ≥98% by HPLC and mass spectrometry, ensures experimental reliability, especially in sensitive models such as stem cell-derived organoids. Storage recommendations are strict: desiccated at -20°C, with prompt usage of solutions to preserve activity.

Receptor Specificity and Signaling Cascade

The physiological potency of Gastrin I (human) is mediated by its high-affinity binding to the CCK2 receptor (also known as the gastrin/CCK-B receptor), a G protein-coupled receptor abundantly expressed on gastric parietal cells and certain gastrointestinal endocrine cells. Upon ligand engagement, the receptor initiates a complex receptor-mediated signal transduction cascade involving phospholipase C activation, intracellular calcium mobilization, and protein kinase C stimulation. This ultimately enhances the activity of the H⁺/K⁺-ATPase proton pump, driving increased gastric acid secretion—a process foundational to both physiological digestion and pathophysiological states such as hypergastrinemia and peptic ulcer disease.

Mechanism of Action: From CCK2 Receptor Agonism to Proton Pump Activation

As a CCK2 receptor agonist, Gastrin I (human) exemplifies the archetype of a peptide hormone that translates extracellular signals into precise intracellular responses. The sequence of events begins with ligand binding, receptor conformational change, and Gq protein activation. This triggers phospholipase C-mediated hydrolysis of PIP₂ into IP₃ and DAG, with subsequent IP₃-dependent release of Ca²⁺ from intracellular stores. Elevated cytosolic Ca²⁺ activates protein kinases and promotes vesicular trafficking of the H⁺/K⁺-ATPase to the apical membrane, culminating in robust proton pump activation and acid secretion.

This pathway is not merely of academic interest; it is central to the pathogenesis of multiple gastrointestinal disorders and represents a therapeutic target for proton pump inhibitors and CCK2 receptor antagonists.

Advances in Human Intestinal Organoid Models: A New Frontier for Gastrin I Research

Limitations of Traditional Models

Historically, studies of gastric acid secretion pathways and receptor signaling have relied on animal models or immortalized cell lines such as Caco-2. However, these systems often fail to recapitulate the complexity and species-specific aspects of human gastrointestinal physiology, particularly in the context of drug metabolism and transporter expression.

hiPSC-Derived Intestinal Organoids: Scientific Breakthroughs

The emergence of human pluripotent stem cell (hiPSC)-derived intestinal organoids marks a transformative advance, as described by Saito et al. in their seminal study (2025). These three-dimensional organoids encompass the full range of intestinal epithelial cell types—including enterocytes, goblet cells, enteroendocrine cells, and Paneth cells—generated by directed differentiation protocols involving Wnt, FGF4, R-spondin, Noggin, and EGF. The resulting organoids are self-renewing, genetically stable, and can be cryopreserved for long-term studies.

Importantly, when organoids are seeded as two-dimensional monolayers, they yield mature intestinal epithelial cells (IECs) that express functional drug transporters (P-gp) and cytochrome P450 enzymes (CYP3A), establishing a robust platform for pharmacokinetic and physiological studies.

Integrating Gastrin I (human) into Organoid-Based Research

Gastrin I (human) provides a critical tool for dissecting CCK2 receptor signaling and proton pump activation within these advanced models. Leveraging the high purity and stability of Gastrin I (human), researchers can now probe how parietal cell-like populations within organoids respond to physiological and pharmacological stimuli, monitor acid secretion dynamics, and assess the impact of candidate drugs or genetic perturbations on the gastric acid secretion pathway. This approach not only mirrors, but also surpasses, the physiological relevance of traditional in vitro methods.

Comparative Analysis: Gastrin I (human) in Organoids Versus Conventional Systems

Earlier content, such as the article "Gastrin I (human): Decoding Proton Pump Activation in Int...", provides a thorough exploration of proton pump activation within next-generation organoid models. However, our analysis extends this by integrating the latest stem cell differentiation protocols and focusing on the interplay between CCK2 receptor signaling and multi-lineage organoid architecture. We further contextualize the use of Gastrin I (human) in evaluating drug metabolism and transporter dynamics, thereby offering a holistic view that interlinks acid secretion with pharmacokinetic profiling.

Whereas prior works, such as "Gastrin I (human): Advancing CCK2 Receptor Pathway Research", emphasize the peptide's role as a CCK2 receptor agonist in classic physiology studies, our article uniquely examines its value within hiPSC-derived organoid systems—addressing a gap in the literature regarding translational and preclinical modeling using human-specific tissue constructs.

Advanced Applications in Gastrointestinal Disorder Research and Drug Discovery

Modeling Disease and Therapeutic Response

The integration of Gastrin I (human) into organoid platforms enables unprecedented fidelity in modeling gastrointestinal disorders such as Zollinger-Ellison syndrome, gastrinomas, and peptic ulcer disease. By manipulating organoid genetics or microenvironmental conditions, researchers can recapitulate disease phenotypes and assess the efficacy of CCK2 receptor antagonists and proton pump inhibitors in a controlled, human-derived context.

Pharmacokinetic and Toxicological Studies

Building on the methodology described by Saito et al. (2025), the use of Gastrin I (human) in hiPSC-derived IECs allows for the study of drug absorption, metabolism, and transporter function under physiologically relevant conditions. This model addresses key limitations of animal models and cancer-derived cell lines, offering species-specific insights into drug–receptor interactions, off-target effects, and metabolic clearance pathways. Such applications are critical for preclinical screening and for identifying potential liabilities early in the drug development process.

Exploring CCK2 Receptor Signaling Complexity

Recent studies have highlighted the multifaceted roles of the CCK2 receptor in modulating not only gastric acid secretion but also cell proliferation, differentiation, and survival within the gastrointestinal tract. Organoid models, when stimulated with Gastrin I (human), provide a versatile system to untangle these pleiotropic effects and to investigate how receptor signaling contributes to tissue homeostasis and disease progression.

Best Practices for Experimental Use of Gastrin I (human) in Organoid Systems

To maximize experimental reproducibility and data quality, researchers should adhere to the following guidelines when employing Gastrin I (human) in organoid models:

• Reconstitution and Handling: Dissolve the lyophilized peptide in DMSO at ≥21 mg/mL immediately prior to use. Avoid aqueous or alcoholic solvents due to insolubility.
• Stability: Store the peptide desiccated at -20°C to preserve bioactivity. Prepared solutions should be used promptly; avoid long-term storage.
• Dosing and Controls: Titrate peptide concentrations to optimize CCK2 receptor activation without eliciting off-target effects. Include vehicle and negative controls to validate specificity of response.
• Readouts: Employ endpoint assays (e.g., acid secretion, gene expression, transporter activity) tailored to the organoid system and experimental question.

For further protocol enhancements and troubleshooting strategies in advanced platforms, readers may consult "Gastrin I (human): Precision Tools for Gastric Acid Pathw...", which provides complementary technical guidance. Our article, by contrast, focuses on the strategic integration of organoid modeling with translational research applications.

Conclusion and Future Outlook

The confluence of Gastrin I (human)—an established CCK2 receptor agonist and gastric acid secretion regulator—with the latest hiPSC-derived intestinal organoid models is accelerating progress in gastrointestinal physiology and disease research. By enabling precise manipulation of CCK2 receptor signaling and acid secretion pathways within human tissue constructs, this approach paves the way for high-throughput pharmacokinetic screening, pathophysiological modeling, and the development of next-generation therapies for gastrointestinal disorders.

As organoid platforms continue to evolve, incorporating additional cell types, microenvironmental cues, and patient-derived materials, the experimental utility of Gastrin I (human) will only expand—ushering in a new era of translational research that bridges basic science and clinical innovation.